The absolute oral bioavailability of XXXX in @entity235 and @entity1 .

@entity1 @entity3761 @entity15353 @entity235 @entity14086 @entity1201
The absolute oral bioavailability of @entity3761 ( @entity15353 ) was established in @entity235 and healthy volunteers by comparing AUC's after oral and intravenous administration. Five female inbred beagles each received 100 mg @entity15353 orally and intravenously as a bolus injection in a randomized cross-over study. @entity15353 serum concentrations were determined using HPLC. After both routes of administration, linear pharmacokinetics were observed, the elimination half-life (t1/2) amounting between 5.8 and 10.2 h. After oral administration, AUC values between 56.1 and 99.2 mg X h X l-1 were found, while after intravenous administration AUC's were between 63.5 and 98.1 mg X h X l-1. The absolute oral bioavailability, corrected for differences in t1/2, averaged 107 +/- 9% (SD). A similar study was carried out in 2 female and 3 male healthy volunteers. The intravenous dose was reduced to 50 mg and given as an infusion. Pharmacokinetics were linear after both routes of administration. The t1/2 values amounted between 15.6 and 30.4 h. AUC's ranged from 24.0 to 75.4 mg X h X l-1 after oral administration and from 13.3 to 37.5 mg X h X l-1 after intravenous infusion of half of the oral dose. The absolute, t1/2-corrected oral bioavailability was calculated to be 86 to 104%. Complete bioavailability of @entity15353 was demonstrated in @entity235 and healthy volunteers. The method used in this study might help to detect possible @entity15353 in @entity1201 and @entity14086 @entity1 .
